Clinical Updates & Insights

Share

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

Stay Informed
Get the latest information on MSK’s cancer treatments and research sent straight to your inbox with our monthly clinical updates e-newsletter OncoNotes.
Newsletter Sign Up
217 Clinical Updates found
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer
Neoadjuvant and Adjuvant Pembrolizumab with Standard-of-Care Significantly Improves Event-Free Survival in Head and Neck Cancer

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.
Doctor and patient shaking hands
ASCO 2025 Research Roundup: MSK Presents Practice-Changing Advances in Cancer Research

MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.
Physician looking at breast imaging
ASCO 2025 News: Groundbreaking Survival Advances for Patients with ER+/HER2- Advanced Breast Cancer

Two new therapy options have demonstrated significant advances in survival outcomes for select patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Both studies were presented today at the 2025 ASCO Annual Meeting in Chicago and simultaneously published in The New England Journal of Medicine.
Radiation therapy during surgery with brachytherapy
Brachytherapy for Brain Metastases

As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.
Vivian Strong, MD
Vivian Strong, MD, Gives a U.S. Perspective on Gastric Cancer at the 16th International Gastric Cancer Congress

Memorial Sloan Kettering’s Vivian Strong, MD, FACS, addressed peers from around the world in May 2025 at the 16th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global Fight for Innovation, the U.S. Perspective,” as the meeting’s Jin Pok Kim Lecturer.
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research
AACR 2025 Research Roundup: Highlights of MSK’s Advances in Oncology Research

Memorial Sloan Kettering Cancer Center (MSK) experts presented their latest advances in oncology research at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25 to 30 in Chicago.
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer
Secondary Rectal Cancer After Radiotherapy for Prostate Cancer Differs From Primary Rectal Cancer

Patients with secondary rectal cancer after radiotherapy for prostate cancer have shorter survival compared with matched treatment-naïve patients. However, a new study by investigators at MSK has found distinct differences in patient characteristics, available treatment options, and tumor biologic characteristics that may explain the gap.
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma
Overcoming Challenges with CAR T Cell Therapy for Patients with Non-Hodgkin Lymphoma

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.
Clinical Trials of New Stereotactic Radiosurgery Strategies for Lung Cancer Brain Metastases
Clinical Trials of New Stereotactic Radiosurgery Strategies for Lung Cancer Brain Metastases

Stereotactic radiosurgery (SRS) is increasingly used to treat brain metastases. The technique uses advanced, computer-guided imaging to deliver a highly targeted and intense dose of photon radiation. Since the radiation dose conforms to the three-dimensional shape and size of the target lesion, there is minimal exposure to the rest of the brain and fewer side effects than with standard radiation techniques.
Clinicopathologic and Genomic Discoveries in Metastatic Lung Cancer Add to Default shortcuts
Clinicopathologic and Genomic Discoveries in Metastatic Lung Cancer

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) surveillance. However, if patients with a high risk of brain metastasis after surgical resection can be identified, surveillance and prophylactic treatment with CNS-directed therapies may improve outcomes.